Hedgehog signaling pathway

StemSynergy Therapeutics’ Notch1-Selective Small Molecule Inhibitor Prevents Tumor Growth by Ablation of Cancer Stem Cells

Retrieved on: 
Wednesday, April 14, 2021

StemSynergy Therapeutics, Inc., who collaborated on this study holds worldwide exclusivity to develop these molecules for the clinic.\n"The Notch pathway is an extremely attractive target for cancer therapeutics, as it is a critical driver of many human cancers.

Key Points: 
  • StemSynergy Therapeutics, Inc., who collaborated on this study holds worldwide exclusivity to develop these molecules for the clinic.\n"The Notch pathway is an extremely attractive target for cancer therapeutics, as it is a critical driver of many human cancers.
  • "Specifically, NADI-351 clears cancer stem cells by starving them of Notch signaling and causes cell death in tumors, including esophageal and triple-negative breast cancer.
  • At the same time this breakthrough science is being published, StemSynergy Therapeutics is developing this class of compound for clinical evaluation.
  • Our mission is to optimize efficacy against the pathways required to drive cancer stem cells, such as the Wnt, Sonic Hedgehog and Notch signaling pathways.

Global Hedgehog Pathway Inhibitors Pipeline Insight Report 2021: Key Products by Pfizer, Pulmatrix, Eli Lilly and Co, Suzhou Kintor Pharmaceuticals, & IMPACT Therapeutics - ResearchAndMarkets.com

Retrieved on: 
Friday, February 19, 2021

The "Hedgehog Pathway Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hedgehog Pathway Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "Hedgehog Pathway Inhibitors - Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Hedgehog Pathway Inhibitors pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Hedgehog Pathway Inhibitors R&D.
  • Hedgehog Pathway Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Trade, Track, And Learn Crypto With Hedgehog

Retrieved on: 
Tuesday, January 26, 2021

At Hedgehog, we care about teaching beginners so they can avoid all the pitfalls we fell into when we were getting started," said Taylor Culbertson, co-founder and CEO of Hedgehog.

Key Points: 
  • At Hedgehog, we care about teaching beginners so they can avoid all the pitfalls we fell into when we were getting started," said Taylor Culbertson, co-founder and CEO of Hedgehog.
  • "All the data on blockchains are public, and Hedgehog puts it all in one place," remarked Colton Dillion, co-founder and CTO of Hedgehog.
  • Hedgehog is a one-stop shop for all your cryptocurrency needs, allowing people to trade on almost any exchange, track all their wallets, and learn about every cryptocurrency.
  • Unify all your crypto services on one platform with Hedgehog.

Endeavor BioMedicines Launches with $62 Million Series A Financing and Mission to Reverse the Course of Devastating Pulmonary Disease

Retrieved on: 
Thursday, January 7, 2021

Endeavor BioMedicines, a biotechnology company developing new treatments targeting the underlying causes of pulmonary fibrosis, today announced it has raised $62 million in a Series A financing.

Key Points: 
  • Endeavor BioMedicines, a biotechnology company developing new treatments targeting the underlying causes of pulmonary fibrosis, today announced it has raised $62 million in a Series A financing.
  • Emerging preclinical and clinical evidence shows the Hedgehog signaling pathway, which is implicated in chronic wound healing, plays a critical role in IPF disease pathology.
  • Studied in 176 subjects to date, taladegib has been shown to safely and effectively inhibit the Hedgehog pathway.
  • Endeavor intends to initiate a Phase 2 study of taladegib as a monotherapy in patients with IPF in the second quarter of 2021.

2020 Market Spotlight: Basal Cell Carcinoma - ResearchAndMarkets.com

Retrieved on: 
Friday, April 17, 2020

The "Market Spotlight: Basal Cell Carcinoma (2020)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Market Spotlight: Basal Cell Carcinoma (2020)" report has been added to ResearchAndMarkets.com's offering.
  • This Market Spotlight covers the basal cell carcinoma market, comprising key marketed and pipeline drugs, epidemiology, recent events and analyst opinion, clinical trials, upcoming events, probability of success, patent information, and licensing and acquisition deals.
  • The approved drugs in the basal cell carcinoma space target the immune system, thymidylate synthase, reactive oxygen species/free radicals, and Hedgehog signaling pathway.
  • Roche leads industry sponsors with the highest overall number of clinical trials for basal cell carcinoma, followed by Novartis.

INHIBITOR Therapeutics Receives prostate cancer IND Clearance from FDA

Retrieved on: 
Wednesday, January 22, 2020

Nicholas J. Virca, INHIBITOR's President and CEO, said: "Following a face-to-face End-of-Phase-2 meeting with FDA last October and our submission of an IND application thereafter, I am pleased to announce that we have received IND clearance for our PREDICT trial.

Key Points: 
  • Nicholas J. Virca, INHIBITOR's President and CEO, said: "Following a face-to-face End-of-Phase-2 meeting with FDA last October and our submission of an IND application thereafter, I am pleased to announce that we have received IND clearance for our PREDICT trial.
  • INHIBITOR Therapeutics, Inc. (OTCQB: INTI) is a pharmaceutical development company that discovers, develops and plans to commercialize innovative therapeutics to inhibit the progression of cancerous and non-cancerous proliferation disorders.
  • INHIBITOR is the exclusive U.S. licensee of SUBA-Itraconazole in certain fields, including prostate and lung cancer.
  • Based on published research, INHIBITOR believes that inhibiting the Hedgehog pathway could delay or possibly prevent development and progression of certain cancers, such as prostate cancer, in humans.

INHIBITOR Therapeutics Submits Investigational New Drug Application for Treatment of Patients with Late-Stage Prostate Cancer

Retrieved on: 
Monday, November 25, 2019

During that meeting, we gained FDA guidance and agreement on our protocol and statistical analysis plan for our proposed PREDICT trial.

Key Points: 
  • During that meeting, we gained FDA guidance and agreement on our protocol and statistical analysis plan for our proposed PREDICT trial.
  • FDA indicated that we can follow the 505(b)(2) regulatory pathway given previous FDA approval of itraconazole.
  • Clinical studies have shown SUBA-Itraconazole to have greater bioavailability than generic itraconazole, a drug approved by FDA for the treatment of certain fungal infections.
  • Based on published research, INHIBITOR believes that inhibiting the Hedgehog pathway could delay or possibly prevent development and progression of certain cancers, such as prostate cancer, in humans.

The global hedgehog pathway inhibitors market at a CAGR of over 11% during the forecast period

Retrieved on: 
Monday, September 16, 2019

Global Hedgehog Pathway Inhibitors Market: About this market

Key Points: 
  • Global Hedgehog Pathway Inhibitors Market: About this market
    This hedgehog pathway inhibitors market analysis considers sales from both basal cell carcinoma (BCC) and acute lymphoblastic leukemia (AML) products.
  • Also, our global hedgehog pathway inhibitors market report looks at factors such as high-risk factors for BCC and AML, growth of geriatric population, and increasing awareness about BCC and AML.
  • Global Hedgehog Pathway Inhibitors Market: Overview
    The abnormal regulation of the Hedgehog pathway is largely linked to the development of cancer types such as BCC and AML.
  • This increasing awareness will lead to the expansion of the global hedgehog pathway inhibitors market at a CAGR of over 11% during the forecast period.

Global Hedgehog Pathway Inhibitors Market 2019-2023 | 11% CAGR Projection Over the Next Five Years | Technavio

Retrieved on: 
Thursday, September 5, 2019
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20190905005776/en/
    Technavio has announced its latest market research report titled global hedgehog pathway inhibitors market 2019-2023.
  • In addition, the growth of geriatric population is expected to further boost the growth of the hedgehog pathway inhibitors market.
  • The high risk factors for BCC and AML is the major reason for the growth of the hedgehog pathway inhibitors market.
  • This increases the prevalence of AML and BCC among aged people, which will fuel the demand for hedgehog pathway inhibitors.

Global Basal Cell Carcinoma Market Spotlight 2019: Key Marketed and Pipeline Drugs, Epidemiology, Clinical Trials, Patents, Licensing and Acquisition Deals, Revenue Forecasts

Retrieved on: 
Wednesday, June 19, 2019

This Market Spotlight report covers the basal cell carcinoma market, comprising key marketed and pipeline drugs, epidemiology, clinical trials, upcoming events, probability of success, patent information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts

Key Points: 
  • This Market Spotlight report covers the basal cell carcinoma market, comprising key marketed and pipeline drugs, epidemiology, clinical trials, upcoming events, probability of success, patent information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts
    The approved drugs in the basal cell carcinoma space target the immune system, thymidylate synthase, and hedgehog signaling pathway.
  • The majority of industry-sponsored drugs in active clinical development for basal cell carcinoma are in Phase II, with two drugs in Phase III.
  • There have been five licensing and asset acquisition activities involving basal cell carcinoma drugs during 2014-19.
  • Roche and Bausch Health have the highest number of completed clinical trials for basal cell carcinoma, with 15 and 14 trials, respectively.